Gramma Posted - 2 hours ago

$MRK

DEXWireNews Posted - 3 hours ago

🚀 $NCNA stock surges 185% after encouraging data from its melanoma treatment combo with $MRK's Keytruda! 🧬 ⭐️ Learn More About $NCNA 📱Download our Mobile App » https://link-to.app/dexwirenews

TheProphetOfProfit Posted - 6 hours ago

$MRK is at multi-month downtrend resistance, as well as the 50day sma. These have both been strong resistances here since late June. Odds are, this rejects this resistance yet again.

Idvst8 Posted - 7 hours ago

$MRK - Hey, MERCK. I think it is time you spend some Money. $IOVA $VKTX

drjtiger Posted - 7 hours ago

$MRK 👏

briefingcom Posted - 8 hours ago

$MRK: Merck: Antennova releases latest data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240916060649MRK&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

tedevan Posted - 8 hours ago

$AMGN $MRK $ESPR

TeresaTrades Posted - 9 hours ago

Largest CALL OI decreases $SIRI $NVDA $MRK $MSTR $MO

Invest2pro Posted - 17 hours ago

$ESPR Hey Esperion my wife can make a commercial for NEXLIZET, she has No symptoms & feels great. She is statin intolerant & she had side effects with Repatha shots, a PCSK9 drug belonging to $AMGN. $MRK Ezetimibe was not strong enough by itself said her doctor & her insurance didn't cover NEXLIZET buy she was able to get it for $25 a month with ASPN specialty pharmacy.

GPS_OS_21_vs_SOC_5 Posted - 1 day ago

$SLS Gps immunotherapy has been effective in all 9 previous trials w Relapse Prevention and Overall Survival benefits directly correlated with Immune Response. - including a Memorial Sloan Kettering Phase 2 for First Remission (CR1) AML, GPS OS of 67.9 months, w SOC at only 28-35 months. - Second MSKCC CR1 P2 AML was halted early due to Efficacy. Gps 47% OS at 3 years vs only 25% wSCOC - a P2 in Second Remission Cr2 at Moffitt Center w a Statistically Significant OS of 21 months, p value .02, ie 98% reproducibility factor, ie will see same results in 98 of 100 trials. - Gps + Keytruda achieved an os of 18.4 months vs 16 w Elahere that was recently FDA approved for platinum refractory ovarian cancer, $IMGN bought for $10.1B - also Dying Gps+Opdivo Mesothelioma patients achieved an Overall Survival of 27.8 Months vs only 28 Weeks with the current standard of care. $BMY $MRK will be among the big pharma bidding for sls once the p3 results are in. Expect a buyout above $10b.

GTradeNYC Posted - 1 day ago

$MRK Out with great news today do you think this cools the hype on $SMMT $BNTX and $TIL https://www.bloomberg.com/news/articles/2024-09-15/merck-s-top-seller-cements-status-in-hard-to-treat-breast-cancer

GTradeNYC Posted - 1 day ago

Lots of positive news coming out of $MRK wonder if it cools the hype on $SMMT $BNTX and $TIL, any thoughts?

DonCorleone77 Posted - 1 day ago

$MRK Merck announces long-term OS data from pivotal Phase 3 KEYNOTE-006 trial Merck announced long-term overall survival data from the pivotal Phase 3 KEYNOTE-006 trial, evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in patients with advanced melanoma. Based on 10 years of follow-up, the data showed sustained improved survival outcomes for patients receiving KEYTRUDA as a single agent compared to ipilimumab in patients with advanced melanoma. These late-breaking data will be presented for the first time during a mini oral session at the European Society for Medical Oncology Congress 2024 and published in the Annals of Oncology. For patients with advanced melanoma, these long-term follow-up data showed the 10-year OS rate for KEYTRUDA was 34.0% versus 23.6% for ipilimumab. KEYTRUDA demonstrated a sustained OS benefit, reducing the risk of death by 29% . At 10 years, KEYTRUDA more than doubled the median OS compared to ipilimumab. To date, KEYTRUDA has demonstrated sustained survival benefits of five years or more across multiple types of cancer, including certain types of melanoma, non-small cell lung cancer, head and neck cancer and bladder cancer. Based on the results from KEYNOTE-006 in December 2015, the U.S. Food and Drug Administration approved KEYTRUDA for the treatment of patients with unresectable or metastatic melanoma.

GTradeNYC Posted - 1 day ago

Sounds like $MRK KEYTRUDA doing well does this still bode well for $SMMT $BNTX $TIL or will cool the recent gains given positive data released today? https://news.nuntiobot.com/article/b3a339ec-2514-4011-9f46-0d0d119fb363

DonCorleone77 Posted - 1 day ago

$MRK $ESALY Merck, Eisai announce results from interim analysis of Phase 3 LEAP-012 trial Merck (MRK) and Eisai (ESAIY) announced results from the first interim analysis of the Phase 3 LEAP-012 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with transarterial chemoembolization compared to TACE alone for the treatment of patients with unresectable, non-metastatic hepatocellular carcinoma. These late-breaking data were presented for the first time during a Presidential Symposium at the European Society for Medical Oncology Congress 2024. After a median follow-up of 25.6 months, KEYTRUDA plus LENVIMA in combination with TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, reducing the risk of disease progression or death by 34% compared to TACE alone. Median PFS was 14.6 months for the KEYTRUDA plus LENVIMA-based regimen versus 10.0 months for TACE alone. At this analysis, a trend toward improvement in overall survival, the trial's other primary endpoint, was observed for the KEYTRUDA plus LENVIMA-based regimen versus TACE alone; the OS data are not mature and did not reach statistical significance at the time of this interim analysis. The trial is continuing, and follow-up of OS is ongoing. The safety profile of the KEYTRUDA plus LENVIMA-based regimen was consistent with that observed in previously reported studies evaluating the combination. Treatment was administered to 237 patients receiving the KEYTRUDA plus LENVIMA-based regimen and 241 patients receiving TACE alone. Treatment-related adverse events occurred in 98.7% of patients receiving KEYTRUDA plus LENVIMA in combination with TACE versus 84.6% of patients receiving TACE alone and led to the discontinuation of both study drugs in 8.4% versus 1.2% of patients, respectively. Serious adverse events were observed in 33.3% of patients receiving KEYTRUDA plus LENVIMA in combination with TACE versus 12.4% of patients receiving TACE alone. Grade 3 or 4 TRAEs occurred in 71.3% of patients receiving KEYTRUDA plus LENVIMA in combination with TACE versus 31.1% for TACE alone, and TRAEs led to death in 1.7% versus 0.4% of patients, respectively. LENVIMA monotherapy is approved for the treatment of patients with unresectable HCC in more than 80 countries, including in the U.S., Europe, China and Japan. KEYTRUDA is approved as a monotherapy for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen in the U.S. and as a monotherapy for the treatment of patients with HCC who have been previously treated with sorafenib or oxaliplatin-containing chemotherapy in China.

Stock_Titan Posted - 1 day ago

$MRK KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) https://www.stocktitan.net/news/MRK/keytruda-r-pembrolizumab-plus-chemotherapy-before-surgery-and-eim26urr1jr6.html

DonCorleone77 Posted - 1 day ago

$MRK Merck announces OS results from pivotal Phase 3 KEYNOTE-A18 trial Merck announced the first presentation of overall survival results from the pivotal Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with concurrent chemoradiotherapy for newly diagnosed patients with high-risk locally advanced cervical cancer. At a median follow-up of 29.9 months, KEYTRUDA in combination with concurrent CRT reduced the risk of death by 33% versus concurrent CRT alone for these patients. For patients who received the KEYTRUDA-based regimen, the 36-month OS rate was 82.6% versus 74.8% for those who received concurrent CRT alone. Median OS was not reached in either group. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified. KEYNOTE-A18 is one of four Phase 3 studies of a KEYTRUDA-based regimen in an earlier stage of cancer to demonstrate an OS benefit, in addition to KEYNOTE-522 in newly diagnosed, high-risk early-stage triple-negative breast cancer and KEYNOTE-671 in resectable stage II, IIIA or IIIB non-small cell lung cancer, as well as KEYNOTE-564 in renal cell carcinoma for patients at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. These results are being discussed with regulatory authorities worldwide. As previously reported, KEYNOTE-A18 met its other primary endpoint of progression-free survival in 2023. These PFS data were presented at the ESMO Congress 2023 and supported the U.S. Food and Drug Administration's approval of KEYTRUDA in combination with CRT for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer in January 2024. In the U.S., KEYTRUDA has two additional approved indications in cervical cancer: in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 [Combined Positive Score greater than or equal to1] as determined by an FDA-approved test; and as a single agent, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 as determined by an FDA-approved test. As announced, data spanning more than 20 types of cancer are being presented from Merck's broad oncology portfolio and investigational pipeline at the ESMO Congress 2024. KEYNOTE-A18, also known as ENGOT-cx11/GOG-3047, is a randomized, double-blind Phase 3 trial sponsored by Merck and conducted in collaboration with the European Network for Gynaecological Oncology Trial groups and the GOG Foundation investigating KEYTRUDA in combination with CRT compared to placebo plus concurrent CRT for the treatment of newly diagnosed high-risk locally advanced cervical cancer where patients are treated with definitive intent. The primary endpoints are PFS and OS, and secondary endpoints include complete response rate, objective response rate and safety. The trial enrolled 1,060 patients who were randomized 1:1 to receive: KEYTRUDA every three weeks for five cycles concurrent with cisplatin weekly for five cycles radiotherapy, followed by KEYTRUDA every six weeks for 15 cycles; Placebo IV Q3W for five cycles concurrent with cisplatin weekly for five cycles and radiotherapy, followed by placebo IV Q6W for 15 cycles. The safety profile of KEYTRUDA was consistent with that observed in previously reported studies. Grade greater than or equal to 3 treatment-related adverse eventsoccurred in 69.1% of patients receiving KEYTRUDA plus concurrent CRT versus 61.3% of patients receiving placebo plus concurrent CRT. No new safety concerns were identified. Immune-mediated adverse events of any grade occurred in 39% of patients receiving the KEYTRUDA regimen and 17% of patients receiving the placebo regimen. Grade 3-5 immune-mediated AEs occurred in 4.7% versus 1.3%, respectively. The most common of these all-grade immune-mediated AEs was hypothyroidism in patients receiving the KEYTRUDA regimen. Immune-mediated AEs led to one death among patients receiving the KEYTRUDA regimen.

DonCorleone77 Posted - 1 day ago

$MRK Merck announces OS results from final analysis of Phase 3 KEYNOTE-811 trial Merck announced overall survival results from the final analysis of the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-positive gastric or gastroesophageal junction adenocarcinoma. The data are being presented during a proffered paper session at the European Society for Medical Oncology Congress 2024 and also simultaneously published in the New England Journal of Medicine. After a median follow-up of 50.2 months, the KEYTRUDA regimen demonstrated a statistically significant and clinically meaningful improvement in OS in the intention-to-treat HER2-positive advanced gastric or GEJ study population, reducing the risk of death by 20% compared to trastuzumab and chemotherapy alone. For patients who received the KEYTRUDA regimen, median OS was 20.0 months versus 16.8 months for patients receiving trastuzumab plus chemotherapy alone. The KEYTRUDA regimen also demonstrated a clinically meaningful improvement in OS in patients whose tumors expressed PD-L1, reducing the risk of disease progression or death by 21% compared to trastuzumab and chemotherapy alone in these patients. Median OS was 20.1 months for patients with tumors expressing PD-L1 receiving the KEYTRUDA regimen versus 15.7 months for patients receiving trastuzumab and chemotherapy alone. In the study, 85% of patients' tumors expressed PD-L1. In the U.S., KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma whose tumors express PD-L1 as determined by an FDA-approved test. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval of this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Since the FDA's accelerated approval, the trial has met its dual primary endpoints of progression-free survival and OS. These results have been shared with regulatory authorities worldwide.

Stock_Titan Posted - 1 day ago

$MRK Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma https://www.stocktitan.net/news/MRK/ten-year-data-for-merck-s-keytruda-r-pembrolizumab-demonstrates-504g0sz7ujnj.html

GreenEnergy2022 Posted - 2 days ago

$ALT So if you take Ozempic, and you feel you lose a lot muscle, you know there will be a GLP1 in phs3 soon coming to market, which will make you save about 100% more in muscle. Better GLP1 drugs is coming to the market soon. Pemv is for those who wants to fat lose fat but keep their muscle. In addition, on the MASH part, 75% liver fat reduction. - VAT was reduced by 28.3% at Week 48 compared to a 19.5% loss in subcutaneous adipose tissue. And this from a company priced at only 550 mcap. Something to consider to acquire from BP`s such as: $NVO $MRK $RHHBY $AZN

FrnkTss Posted - 2 days ago

$MRK 117 https://youtu.be/OhgUexAurF0

FrnkTss Posted - 2 days ago

https://youtu.be/OhgUexAurF0 $MRK $95 is support

Stock_Titan Posted - 2 days ago

$MRK KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma https://www.stocktitan.net/news/MRK/keytruda-r-pembrolizumab-plus-lenvima-r-lenvatinib-in-combination-zbr592mw1ald.html

Stock_Titan Posted - 2 days ago

$MRK Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer https://www.stocktitan.net/news/MRK/merck-s-keytruda-r-pembrolizumab-plus-chemoradiotherapy-crt-reduced-xaxq7nd9hfu3.html

Stocksrunner Posted - 2 days ago

🚨 Big Money Moves! Unusual Options Activity to Watch This Week! $AAPL Whales betting on calls! $MRK Bearish whispers from insiders! $CAT Bulls stacking up for a breakout! $W & $BNTX Bears making bold moves! Keep these on your radar for Monday! 😎 stocksrunner.com/posts/1142

GemsBot Posted - 2 days ago

8 of 11 $MRK $MSFT $NKE Experienced traders are also using tick, volume, range or price change intervals to suit their own trading profile … see 9/11

Nosh Posted - 2 days ago

$SMMT $BNTX Fast Money on CNBC..."BNTX over SMMT at this Market Cap. Stay away from $MRK."

Jimmyboy29 Posted - 3 days ago

$MRK fidelity sold my $115 calls at 2:45 while price was at 115.35 then 5mins later merck goes to 116.10 and I miss $900 so screwed up.

cubie Posted - 3 days ago

@Redboal @GambitMentality @Hockeyfreak3131 @ThinkRealHard but next week's $mrk calls even more cray cray than puts

cubie Posted - 3 days ago

$mrk @GambitMentality @Hockeyfreak3131 similar to $unh but not as much premium as unh but still huge